EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 474 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... July 1, 2021 New on NCI’s Websites for March 2023 March 24, 2023 Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients... June 1, 2026 After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby November 25, 2020 Load more HOT NEWS FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia De qué manera el seguimiento de los síntomas mejora la atención... FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma First treatment approved in England for advanced bile duct cancer
